Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04469569 · ClinicalTrials.gov registry record · NA
Provider-Focused Intervention for Maximizing HPV Vaccine Uptake in Young Cancer Survivors
A NA study of Papillomavirus Vaccines, sponsored by University of Alabama at Birmingham.
- Active
- Registry status
- NA
- Development phase
- 5,196
- Enrollment target
- 6
- Study locations
NCT04469569: Active NA study of Papillomavirus Vaccines, sponsored by University of Alabama at Birmingham.
NCT04469569 is a NA study of Papillomavirus Vaccines that is active but no longer recruiting, run by University of Alabama at Birmingham. The registered enrollment target is 5,196 participants, above the 2,613-participant average among 4 other Papillomavirus Vaccines trials with a reported enrollment target (99% higher). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04469569, a NA study of Papillomavirus Vaccines, is active but no longer recruiting, sponsored by University of Alabama at Birmingham.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 5,196 participants
- Enrollment target
- 6
- Study locations
Study Summary
The focus of this research is on increasing the uptake of the human papillomavirus (HPV) vaccine in young cancer survivors, a vulnerable population at high risk for developing new cancers (such as cervical and anal cancer) caused by persistent HPV infection. An effective vaccine exists that can prevent these cancers, but HPV vaccine uptake is low among young cancer survivors. This research will evaluate the effectiveness and implementation of an evidence-based intervention, adapted for use by healthcare providers in pediatric oncology clinics, to increase the uptake of HPV vaccine among young cancer survivors 9-17 years of age. Results of this research will provide important information that can be used to implement new strategies to increase the uptake of the HPV vaccine among young cancer survivors.
Primary Outcome
The primary outcome was the percentage of cancer survivors, age 9-17y and ≥1y post-completion of cancer therapy, who completed a clinic visit (in-person or via telehealth) at one of the participating sites during the study year, and who had initiated the HPV vaccine series as of the final day of the study year, as measured via state vaccine registry records.
Conditions Studied
Interventions
- BEHAVIORAL HPV-PROTECT
Study Locations (6)
Alabama
- University of Alabama at Birmingham - Birmingham
Georgia
- Emory University - Atlanta
Minnesota
- University of Minnesota - Minneapolis
North Carolina
- Wake Forest University Health Sciences - Winston-Salem
Oregon
- Oregon Health and Science University - Portland
Texas
- Baylor College of Medicine - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,196 participants |
| Start Date | 2021-02-01 |
| Est. Completion | 2026-01-31 |
| Phase | NA |
What the registry record for NCT04469569 still lists
NCT04469569 is an interventional study that assigns participants to a tested intervention. Its 5,196 participants enrollment target places it among the larger protocols in the corpus, above the 2,613-participant average among 4 other Papillomavirus Vaccines trials with a reported enrollment target (99% higher).
The record links to 1 condition, with Papillomavirus Vaccines appearing as the primary indexed condition, and to 1 intervention - of which HPV-PROTECT is the first listed.
NCT04469569 lists 6 locations in 6 states (Alabama, Georgia, Minnesota).
Frequently Asked Questions
What is clinical trial NCT04469569 about?
NCT04469569 is a clinical study titled "Provider-Focused Intervention for Maximizing HPV Vaccine Uptake in Young Cancer Survivors". The focus of this research is on increasing the uptake of the human papillomavirus (HPV) vaccine in young cancer survivors, a vulnerable population at high risk for developing new cancers (such as cervical and anal cancer) caused by persistent HPV infection. An effective vaccine exists that can prev...
What is the current status of trial NCT04469569?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 5,196 participants. The study started on 2021-02-01. Estimated completion is 2026-01-31.
What conditions does trial NCT04469569 study?
This clinical trial studies the following conditions: Papillomavirus Vaccines.
What interventions are being tested in trial NCT04469569?
The interventions under investigation include: HPV-PROTECT (BEHAVIORAL).
Who is sponsoring clinical trial NCT04469569?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04469569 being conducted?
This trial has 6 study locations across Alabama, Georgia, Minnesota, North Carolina, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Papillomavirus Vaccines
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ReMARK: Addressing Disparities in Rural HPV-related Cancer Prevention
RECRUITING · NA
-
Impact of Adolescent Vaccine Reminder Notices Sent Via Preferred Method of Communication on HPV Vaccination
ACTIVE NOT RECRUITING · NA
-
Let's K-Talk - HPV Study for Ethnic Koreans
ACTIVE NOT RECRUITING · NA
-
Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05989308 · 5,200 participants · NA
MyChart Proxy Outreach to Parents (MyPOP)
- NCT06008197 · 5,200 participants · Phase 3
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
- NCT05135403 · 5,179 participants
ASSURE WCD Clinical Evaluation - Post Approval Study (ACE-PAS)
- NCT06506344 · 5,250 participants · NA
Syncing Screening and Services for Suicide Prevention Across Health and Justice Systems
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI